Barry Bonds TRT: What Clinicians Should Tell Patients

What the Barry Bonds Case Actually Involved

The BALCO investigation, concluded publicly around 2003 to 2004, alleged that Bonds received a designer anabolic steroid called tetrahydrogestrinone (THG, nicknamed "the clear"), a topical testosterone-epitestosterone blend ("the cream"), human growth hormone, insulin, and erythropoietin. Grand jury testimony leaked to the San Francisco Chronicle described Bonds allegedly telling investigators he used the substances but thought they were flaxseed oil and an arthritis balm. He was convicted of obstruction of justice in 2011; the Ninth Circuit vacated that conviction in 2015 on procedural grounds.

No treating physician publicly confirmed a clinical diagnosis of hypogonadism or any other medical indication for testosterone therapy in Bonds. The alleged use was therefore supraphysiologic doping, not replacement therapy, and clinicians should frame it precisely that way when patients raise the subject.

What the BALCO Substances Were

THG is a synthetic androgen specifically engineered to evade standard urine immunoassay testing. The FDA has never approved THG for any indication. USADA and the World Anti-Doping Agency classified it as a prohibited anabolic agent. The testosterone-epitestosterone "cream" was designed to keep the T/E ratio under the then-standard 6:1 detection threshold used in sports drug testing.

Human growth hormone (somatropin) at supraphysiologic doses increases lean mass modestly but does not improve athletic performance metrics reliably. A Cochrane review of HGH in athletes found no significant improvement in strength or aerobic capacity despite measurable body composition changes. Cochrane Database Syst Rev 2008.

Why Patients Bring Up Bonds by Name

Bonds holds the MLB career home run record (762). Patients, particularly men over 40 asking about TRT, sometimes cite his physical transformation between his early Pittsburgh Pirates years and his San Francisco Giants peak as anecdotal evidence that testosterone "really works." That framing conflates supraphysiologic pharmacologic doping with clinical hormone replacement, and the distinction matters for both safety counseling and expectation setting.

The Clinical Definition of Hypogonadism and Who Qualifies for TRT

Testosterone replacement therapy is indicated for men with confirmed symptomatic hypogonadism, not for performance enhancement. The Endocrine Society's 2018 Clinical Practice Guideline defines hypogonadism as two fasting morning total testosterone measurements below 300 ng/dL on separate occasions, combined with signs or symptoms such as low libido, erectile dysfunction, decreased energy, depressed mood, reduced muscle mass, or osteoporosis. Endocrine Society Guideline, J Clin Endocrinol Metab 2018.

Diagnostic Thresholds

Total testosterone alone is insufficient in borderline cases. Free testosterone calculated from sex hormone-binding globulin (SHBG) adds specificity when total T sits between 300 and 400 ng/dL. The American Urological Association recommends measuring LH and FSH to distinguish primary from secondary hypogonadism before initiating therapy. AUA Testosterone Deficiency Guideline 2018, updated 2022.

Prolactin should be checked when secondary hypogonadism is identified, because a pituitary adenoma changes the therapeutic approach entirely.

What "Normal" Actually Means on a Lab Report

Reference ranges differ by assay and lab. Most current immunoassay platforms report 300 to 1,000 ng/dL as the male adult range. Mass spectrometry-based assays, recommended by the Endocrine Society for borderline results, tend to read 5 to 10% lower than immunoassay. Patients who present a lab result printed from a consumer health app may be seeing a number generated by a different methodology than what your clinic uses. Retest with a consistent, validated assay before making a treatment decision.

Evidence Behind Legitimate TRT: What the Data Show

The Testosterone Trials (TTrials)

The TTrials were a coordinated set of seven double-blind, placebo-controlled trials in 788 men aged 65 and older with total testosterone below 275 ng/dL. Published in the New England Journal of Medicine in 2016, the sexual function trial showed a 1.7-point improvement on the PDAS-II sexual activity scale versus 0.4 points for placebo (P<0.001). NEJM 2016;374:611-624. The physical function trial found no significant improvement in walking distance. Bone mineral density improved significantly in the TTrials bone sub-study. These are the results patients should expect from replacement-dose TRT: modest, real, symptom-targeted improvements, not the dramatic body-composition changes associated with doping.

The TRAVERSE Trial and Cardiovascular Safety

TRAVERSE (N=5,246, mean age 63, mean baseline testosterone 227 ng/dL) was a randomized, placebo-controlled trial of testosterone gel 1.62% dosed to achieve levels of 350 to 750 ng/dL. Published in NEJM in 2023, it found no significant difference in major adverse cardiovascular events (MACE) between testosterone and placebo groups (hazard ratio 0.96, 96% CI 0.78-1.17). NEJM 2023;389:107-117. Atrial fibrillation and acute kidney injury were numerically higher in the testosterone arm, and pulmonary embolism reached statistical significance. Clinicians should incorporate these signals into the informed consent conversation.

Bone Density and Fracture Risk

A meta-analysis of 19 randomized controlled trials (N=1,761) found that TRT increased lumbar spine bone mineral density by a standardized mean difference of 0.48 (95% CI 0.27-0.69) versus placebo. J Clin Endocrinol Metab 2017;102:1861-1870. This benefit is most clinically meaningful in men with osteoporosis or fracture history, which is a separate population from the performance-focused patients who cite Bonds.

Supraphysiologic Testosterone vs. TRT: A Side-by-Side Clinical Picture

Patients who ask "what was Barry Bonds taking, and can I get something like that?" deserve a direct answer. The table below makes the pharmacologic contrast explicit.

| Parameter | Evidence-Based TRT | Supraphysiologic Doping | |---|---|---| | Target serum total T | 400-700 ng/dL (mid-normal) | 1,500-3,000+ ng/dL | | Typical weekly testosterone dose | 50-100 mg testosterone cypionate IM or equivalent | 300-1,000 mg/week or more, often stacked | | Estradiol management | Monitor; aromatase inhibitor only if symptomatic | Often suppressed aggressively with anastrozole | | Hematocrit monitoring | Yes; hold if >54% per Endocrine Society | Rarely monitored; erythrocythemia is a doping goal | | Cardiovascular risk | No MACE increase at guideline doses (TRAVERSE) | Increased LVH, dyslipidemia, sudden cardiac death reports | | Hepatotoxicity | Minimal with injectable or transdermal | Significant with oral 17-alpha alkylated androgens | | Fertility impact | Suppresses spermatogenesis; reversible in most | Severe, sometimes prolonged suppression | | Legal/regulatory status | FDA-approved; Schedule III controlled substance with valid Rx | Illegal without Rx; banned by all sports federations |

Human Growth Hormone: Separating the BALCO Narrative from Clinical Use

HGH (somatropin) has specific FDA-approved indications: adult growth hormone deficiency confirmed by stimulation testing, short bowel syndrome, and AIDS-related wasting. FDA-approved labeling for somatropin products. It is not approved for anti-aging, athletic performance, or body composition enhancement in otherwise healthy adults.

What the Evidence Shows for HGH in Athletes

The Cochrane review cited above found that HGH administration to athletes increased lean body mass by 2.1 kg on average but produced no detectable improvement in strength, power, or aerobic capacity, and caused soft tissue edema and arthralgias in a meaningful proportion of participants. Cochrane Database Syst Rev 2008. The mass gain was essentially fluid, not contractile muscle.

IGF-1 as a Biomarker

Exogenous HGH raises IGF-1. Clinicians evaluating a patient for adult growth hormone deficiency should measure IGF-1 and, if low for age, confirm with an insulin tolerance test or glucagon stimulation test before prescribing. Endocrine Society GH Deficiency Guideline, J Clin Endocrinol Metab 2011. Prescribing somatropin to a patient with a normal IGF-1 is both clinically unsupported and legally risky under the Anti-Drug Abuse Act of 1988 and subsequent federal statutes.

Insulin and EPO: The Rest of the Alleged BALCO Stack

Bonds' grand jury testimony included references to insulin and erythropoietin. These are worth addressing briefly because patients occasionally ask about them.

Insulin

Exogenous insulin in non-diabetic individuals carries acute hypoglycemia risk. There is no approved indication for insulin in euglycemic athletes. Several exercise physiology studies have examined insulin's anabolic signaling role, but no controlled trial supports exogenous insulin administration for muscle hypertrophy in non-diabetic subjects, and the risk-benefit ratio is clearly negative. NEJM 2001;345:1345-1346, correspondence on insulin abuse in sport.

Erythropoietin

Recombinant human erythropoietin (epoetin alfa, darbepoetin) is FDA-approved for anemia of chronic kidney disease, chemotherapy-related anemia, and perioperative anemia reduction. FDA drug label for epoetin alfa. Doping use at supraphysiologic doses increases hematocrit to 50 to 55% or higher, raising whole-blood viscosity and the risk of arterial and venous thrombosis. Several competitive cyclists died in circumstances attributed to EPO abuse during the 1990s, though causation was never formally established in individual cases.

How to Use This Conversation in the Clinic

When a patient asks "what did Barry Bonds take and can I get on that?" the question is actually five questions compressed into one:

1. Am I a candidate for TRT?
2. Will TRT make me look or perform like a professional athlete in his prime?
3. Are there shortcuts beyond TRT?
4. What are the real risks?
5. Is any of this legal?

Address each directly. Do not dismiss the question as naive. Patients who ask about celebrity drug use are often more engaged and more motivated to act on information than patients who come in passively.

Expectation-Setting Language

The Endocrine Society's 2018 guideline states: "We recommend against treating men who have age-related decline in testosterone but who do not meet the biochemical criteria for hypogonadism." J Clin Endocrinol Metab 2018;103:1715-1744. Use that standard as an anchor. A patient with a total testosterone of 450 ng/dL asking about TRT because he saw a transformation attributed to Bonds does not meet the indication.

Fertility Counseling Before Initiation

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis, reducing intratesticular testosterone and spermatogenesis. A 2013 study in the Journal of Clinical Endocrinology and Metabolism found that azoospermia or severe oligospermia developed in approximately 40% of men on injectable testosterone undecanoate within 6 months. J Clin Endocrinol Metab 2013;98:4314-4321. Patients who have not completed their family should be counseled explicitly before starting any testosterone formulation. Clomiphene citrate or human chorionic gonadotropin (hCG) are options for men who want to preserve fertility while addressing hypogonadal symptoms.

Polycythemia Monitoring Protocol

Hematocrit should be checked at baseline, 3 months after initiation, and every 6 to 12 months thereafter. The Endocrine Society recommends withholding or dose-reducing testosterone if hematocrit exceeds 54%. J Clin Endocrinol Metab 2018;103:1715-1744. Venipuncture (therapeutic phlebotomy) is sometimes used in practice but is not formally endorsed in the guideline as a routine management strategy.

The Broader Lesson: Celebrity Cases as Clinical Catalysts

The BALCO case involved at least four professional athletes across multiple sports. The public record from that investigation, including the 2007 book "Game of Shadows" by Mark Fainaru-Wada and Lance Williams based on leaked grand jury transcripts, introduced millions of Americans to the names of specific performance-enhancing drugs. That cultural familiarity means patients sometimes arrive with more terminology than understanding.

A 2020 survey published in JAMA Internal Medicine found that 12.8% of U.S. Adult men reported ever using testosterone therapy, with rates rising sharply in men aged 40 to 64. JAMA Intern Med 2020;180:1391-1393. That is the population most likely to ask about Barry Bonds. Clinicians who can speak fluently about the distinction between doping pharmacology and replacement endocrinology will build trust with this cohort faster than those who deflect the question.

The BALCO investigation also led directly to the Anabolic Steroid Control Act of 2004, which expanded the Schedule III controlled substance list to include THG and dozens of other designer androgens. DEA Diversion Control Division fact sheet on anabolic steroids. Prescribing testosterone without a documented medical indication is a federal violation, and clinicians operating telehealth TRT practices should be especially clear-eyed about documentation requirements.

Key Takeaways for the Clinical Encounter

Patients asking about Barry Bonds and TRT are worth engaging seriously. The case touches on pharmacology, sports history, federal law, and personal health goals simultaneously. A few direct points to make in the room:

• Bonds' alleged use was supraphysiologic doping, not replacement therapy. The two categories share a molecule but nothing else pharmacologically.
• Legitimate TRT targets mid-normal testosterone levels (400 to 700 ng/dL). It reliably improves sexual function and bone density in hypogonadal men. It does not produce the body-composition changes associated with professional doping programs.
• The cardiovascular safety data from TRAVERSE (N=5,246) are generally reassuring for guideline-dosed TRT, with the caveat of increased atrial fibrillation and pulmonary embolism signals that warrant monitoring.
• Fertility suppression is real and often underemphasized in direct-to-consumer TRT marketing. Counsel every patient of reproductive age before prescribing.

Check hematocrit at baseline, at 3 months, and every 6 to 12 months thereafter; withhold testosterone if hematocrit exceeds 54%.